THAR
Tharimmune, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.54
+6.63%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 3.1M | 3.1M | 6.4M | 3.6M | 2.3M |
| SG&A Expense | 17.0M | 17.0M | 6.0M | 5.9M | 4.6M |
| General & Admin Expense | 13.3M | 17.0M | 6.0M | 5.9M | 4.6M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 20.1M | 20.1M | 12.4M | 9.5M | 6.9M |
| Cost and Expenses | 20.1M | 20.1M | 12.4M | 9.5M | 6.9M |
| Operating Income (EBIT) | (20.1M) | (20.1M) | (12.4M) | (9.5M) | (6.9M) |
| Non-Operating | |||||
| Interest Income | 41.4K | 41.4K | 249.9K | 152.6K | — |
| Interest Expense | 28.3K | 28.3K | 13.7K | 16.5K | 1.6M |
| Net Interest Income | 13.1K | 13.1K | 236.2K | 136.1K | (1.6M) |
| Other Non-Op Income/Expense | (22.0M) | (22.0M) | 236.2K | 136.1K | (1.6M) |
| Non-Operating Income (excl Interest) | 22.0M | 22.0M | (222.5K) | (152.6K) | — |
| EBT (Pre-Tax Income) | (42.1M) | (42.1M) | (12.2M) | (9.3M) | (8.5M) |
| Income Tax Expense | (6.2M) | (6.2M) | — | — | — |
| Bottom Line | |||||
| Net Income | (35.9M) | (35.9M) | (12.2M) | (9.3M) | (8.5M) |
| Earnings from Cont. Ops | (35.9M) | (35.9M) | (12.2M) | (9.3M) | (8.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (35.9M) | (35.9M) | (12.2M) | (9.3M) | (8.5M) |
| Per Share | |||||
| Basic EPS | ($2.76) | ($1.12) | ($9.41) | ($107.08) | ($280.77) |
| Diluted EPS | ($2.76) | ($1.12) | ($9.41) | ($107.08) | ($280.77) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 32.0M | 32.0M | 1.3M | 87029 | 30178 |
| Diluted Shares Outstanding | 32.0M | 32.0M | 1.3M | 87029 | 30178 |
| Profitability Metrics | |||||
| EBITDA | (42.1M) | (42.1M) | (12.4M) | (9.1M) | (6.7M) |
| D&A | — | — | (222.5K) | 152.6K | 228.5K |
| EBIT | (42.1M) | (42.1M) | (12.2M) | (9.3M) | (6.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025